Fruquintinib is a medicine used to treat colon or rectal cancer that has spread and kept growing after other treatments. It works by blocking signals that tumors use to grow new blood vessels. It's taken as a capsule by mouth.
Every report comes from a Lived member, sent anonymously.
Have you tried Fruzaqla (Fruquintinib) for Colorectal Cancer?
Fruquintinib, sold as Fruzaqla, is a prescription cancer medicine taken by mouth. It is approved for adults with metastatic colorectal cancer, meaning cancer of the colon or rectum that has spread to other parts of the body, after the main standard treatments have already been used. In practice, it is used once the cancer has kept growing after the usual chemotherapy combinations and targeted drugs. Those typically include chemotherapy built on a fluoropyrimidine (such as fluorouracil), oxaliplatin and irinotecan, and a drug that blocks VEGF (vascular endothelial growth factor, a signal tumors use to grow blood vessels). For tumors without a change in the RAS growth genes, they also include, when appropriate, an antibody that blocks EGFR (epidermal growth factor receptor), another growth signal on cancer cells. Many people taking it have also already tried other later-line tablets such as Lonsurf (trifluridine and tipiracil) or Stivarga (regorafenib). Fruquintinib is not a cure. Its purpose is to slow the cancer and extend life while keeping treatment manageable at home.
Tumors need a steady blood supply to keep growing, and they get it by releasing VEGF, the signal that tells nearby blood vessels to sprout new branches. Fruquintinib blocks the three receptors that receive the VEGF signal, so the message to build new vessels is not passed on. With less new blood vessel growth, the tumor has a harder time getting the oxygen and nutrients it needs. The same signal also helps maintain normal blood vessels, the kidneys' filters and wound healing. That explains why the medicine's typical side effects include higher blood pressure, protein in the urine, bleeding and slower healing.
Fruquintinib comes as capsules (1 mg and 5 mg). The usual starting dose is 5 mg once a day for 21 days, followed by 7 days off, which makes up one 28-day cycle. The cycles repeat for as long as the medicine is helping and side effects stay manageable. It can be taken with or without food, at about the same time each day, and the capsule should be swallowed whole. If a dose is missed and fewer than 12 hours have passed, it can still be taken; otherwise skip it and never take two doses on the same day. If you vomit after a dose, do not take another one; take the next dose as scheduled. Pauses and dose reductions to 4 mg or 3 mg are common ways the oncology team manages side effects, so dose changes should come from them.
Tiredness and weakness are the most common complaints. High blood pressure affects about half of people and often appears within the first two weeks, so tell the care team if home readings run high. Other frequent effects include mouth sores, diarrhea, abdominal pain, a hoarse voice, joint or muscle aches and an underactive thyroid. A hand-foot skin reaction can cause redness, soreness, swelling or blistering on the palms and soles, and should be reported early because a short pause or lower dose usually helps. Blood and urine tests may show raised liver enzymes, protein in the urine or higher cholesterol and triglycerides. Less common effects can be serious. Fruquintinib can cause bleeding, liver injury and infections, and rarely a hole in the bowel or a brain swelling syndrome called PRES. Call the care team right away for bleeding or bruising that is unusual or heavier than expected, severe abdominal pain, yellowing skin or eyes, fever or chills, or new confusion, severe headache or vision changes. Fruquintinib can also raise the risk of blood clots in the arteries, which can cause a heart attack or stroke. Call 911 for new chest pain, sudden weakness, numbness or trouble speaking, a seizure, or bleeding that cannot be controlled with pressure or that causes fainting.
Some medicines speed up the liver enzyme (CYP3A) that breaks down fruquintinib, which can lower the amount in the blood and may make it less effective. The antibiotic rifampin, used mainly for tuberculosis, should be avoided, and others such as efavirenz, an HIV medicine, are best avoided when possible. Share a complete list of prescriptions, over-the-counter medicines and supplements with the oncology team. People taking a blood thinner such as warfarin may need closer blood clotting checks. Because fruquintinib slows wound healing, it is stopped at least 2 weeks before major surgery and not restarted for at least 2 weeks afterward and until the wound has healed. Tell any surgeon or dentist planning a procedure. It is not started while an infection is active or until blood pressure is controlled, and it is not recommended for people with severe liver impairment. Starting it soon after a heart attack, stroke or other serious clot needs careful discussion with the oncologist. Fruquintinib can harm a developing baby. Women who could become pregnant, and men with partners who could, should use effective contraception during treatment and for 2 weeks after the last dose, and breastfeeding should be avoided for the same period. The 1 mg capsules contain the yellow dyes tartrazine and sunset yellow, which can trigger allergic-type reactions, including asthma, in sensitive people, more often in those who react to aspirin.
Fruquintinib is taken at home, but it comes with regular monitoring. Blood pressure is checked weekly during the first month and at least monthly after that, and many people need to start or adjust a blood pressure medicine. Liver tests and urine protein are checked before starting and throughout treatment, and scans are repeated at intervals to see whether the cancer is stable or growing. In the main study of people who had already received most other options, the cancer was held in check for a median of about 3.7 months compared with 1.8 months on placebo (an inactive pill; both groups also received supportive care), and median survival was 7.4 months compared with 4.8 months. A median is the midpoint: half of people did better than this and half did less well. Some people benefit for considerably longer and others for less. Nearly half of people in the trial needed at least one pause in treatment for side effects, and about a quarter needed a lower dose. Treatment usually continues until scans show progression or side effects outweigh the benefit, and decisions at that point often include clinical trials or a focus on comfort and quality of life.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Fruzaqla (Fruquintinib), what you've noticed, or ask the community a question.